RT Journal Article
SR Electronic
T1 Proteomic Characterization of Acute Kidney Injury in Patients Hospitalized with SARS-CoV2 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.09.21267548
DO 10.1101/2021.12.09.21267548
A1 Ishan Paranjpe
A1 Pushkala Jayaraman
A1 Chen-Yang Su
A1 Sirui Zhou
A1 Steven Chen
A1 Ryan Thompson
A1 Diane Marie Del Valle
A1 Ephraim Kenigsberg
A1 Shan Zhao
A1 Suraj Jaladanki
A1 Kumardeep Chaudhary
A1 Steven Ascolillo
A1 Akhil Vaid
A1 Arvind Kumar
A1 Edgar Kozlova
A1 Manish Paranjpe
A1 Ross O’Hagan
A1 Samir Kamat
A1 Faris F. Gulamali
A1 Justin Kauffman
A1 Hui Xie
A1 Joceyln Harris
A1 Manishkumar Patel
A1 Kimberly Argueta
A1 Craig Batchelor
A1 Kai Nie
A1 Sergio Dellepiane
A1 Leisha Scott
A1 Matthew A Levin
A1 John Cijiang He
A1 Mayte Suarez-Farinas
A1 Steven G Coca
A1 Lili Chan
A1 Evren U Azeloglu
A1 Eric Schadt
A1 Noam Beckmann
A1 Sacha Gnjatic
A1 Miram Merad
A1 Seunghee Kim-Schulze
A1 Brent Richards
A1 Benjamin S Glicksberg
A1 Alexander W Charney
A1 Girish N Nadkarni
YR 2022
UL http://medrxiv.org/content/early/2022/08/29/2021.12.09.21267548.abstract
AB Acute kidney injury (AKI) is a known complication of COVID-19 and is associated with an increased risk of in-hospital mortality. Unbiased proteomics using biological specimens can lead to improved risk stratification and discover pathophysiological mechanisms. Using measurements of ∼4000 plasma proteins in two cohorts of patients hospitalized with COVID-19, we discovered and validated markers of COVID-associated AKI (stage 2 or 3) and long-term kidney dysfunction. In the discovery cohort (N= 437), we identified 413 higher plasma abundances of protein targets and 40 lower plasma abundances of protein targets associated with COVID-AKI (adjusted p <0.05). Of these, 62 proteins were validated in an external cohort (p <0.05, N =261). We demonstrate that COVID-AKI is associated with increased markers of tubular injury (NGAL) and myocardial injury. Using estimated glomerular filtration (eGFR) measurements taken after discharge, we also find that 25 of the 62 AKI-associated proteins are significantly associated with decreased post-discharge eGFR (adjusted p <0.05). Proteins most strongly associated with decreased post-discharge eGFR included desmocollin-2, trefoil factor 3, transmembrane emp24 domain-containing protein 10, and cystatin-C indicating tubular dysfunction and injury. Using clinical and proteomic data, our results suggest that while both acute and long-term COVID-associated kidney dysfunction are associated with markers of tubular dysfunction, AKI is driven by a largely multifactorial process involving hemodynamic instability and myocardial damage.Competing Interest StatementGNN and SGC reports grants, personal fees, and non-financial support from Renalytix. GNN reports non-financial support from Pensieve Health, personal fees from AstraZeneca, personal fees from BioVie, personal fees from GLG Consulting, personal fees from Siemens Healthineers from outside the submitted work. IP receives personal fees from Character Biosciences.Funding StatementEUA, GNN, JCH and SGC are partially funded by R01 DK118222. GNN also is supported by R01DK127139, R01HL155915 and R56DK126930.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Icahn School of Medicine Mt. Sinai gave ethical approval for this work using STUDY-20-00338I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available by contacting the senior author, Girish Nadkarni (girish.nadkarni@mountsinai.org). Code is available at https://github.com/Nadkarni-Lab/aki_covid_proteomics